| Literature DB >> 26471361 |
Phillip L Palmbos1, Lidong Wang2, Huibin Yang2, Yin Wang2, Jacob Leflein2, McKenzie L Ahmet2, John E Wilkinson3, Chandan Kumar-Sinha4, Gina M Ney5, Scott A Tomlins4, Stephanie Daignault6, Lakshmi P Kunju4, Xue-Ru Wu7, Yair Lotan8, Monica Liebert9, Mats E Ljungman10, Diane M Simeone11.
Abstract
Bladder cancer is a common and deadly malignancy but its treatment has advanced little due to poor understanding of the factors and pathways that promote disease. ATDC/TRIM29 is a highly expressed gene in several lethal tumor types, including bladder tumors, but its role as a pathogenic driver has not been established. Here we show that overexpression of ATDC in vivo is sufficient to drive both noninvasive and invasive bladder carcinoma development in transgenic mice. ATDC-driven bladder tumors were indistinguishable from human bladder cancers, which displayed similar gene expression signatures. Clinically, ATDC was highly expressed in bladder tumors in a manner associated with invasive growth behaviors. Mechanistically, ATDC exerted its oncogenic effects by suppressing miR-29 and subsequent upregulation of DNMT3A, leading to DNA methylation and silencing of the tumor suppressor PTEN. Taken together, our findings established a role for ATDC as a robust pathogenic driver of bladder cancer development, identified downstream effector pathways, and implicated ATDC as a candidate biomarker and therapeutic target. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26471361 PMCID: PMC4668224 DOI: 10.1158/0008-5472.CAN-15-0603
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701